Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 4 I, 2000, Pages 1172-1178

  Douglas, William W ^a,b   Ryu, Jay H ^a   Schroeder, Darrell R ^a  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; PREDNISONE; STEROID;

ADULT; AGED; APOPTOSIS; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OPEN LUNG BIOPSY; OXYGEN THERAPY; PRIORITY JOURNAL; STEROID THERAPY; SURVIVAL;

EID: 0034054908     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.4.9907002     Document Type: Article

References (36)

1. Katzenstein, A. A., and J. L. Myers. 1998. Stale of the art: idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 157:1301-1315.
2. Bjoraker, J. A., J. H. Ryu, M. K. Edwin, J. L. Myers, H. D. Tazelaar, D. R. Schroeder, and K. P. Offord. 1998. Prognostic significance of histologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 157:199-203.
3. Hubbard, R., I. Johnston, and J. Britton. 1998. Survival in patients with cryptogenic fibrosing alveolitis. Chest 113:396-400.
4. Perez-Padilla, R., J. Salas, R. Chapela, M. Sanchez, G. Carrillo, R. Perez, S. Sansores, M. Gaxiola, and M. Selman. 1993. Mortality in Mexican patients with chronic pigeon breeder's lung compared with those with usual interstitial pneumonia. Am. Rev. Respir. Dis. 148:49-53.
5. Schwartz, D. A., R. A. Helmers, J. R. Galvin, D. S. Van Fossen, K. L. Frees, C. S. Kayton, L. F. Burmeister, and G. W. Hunninghake. 1994. Determinants of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 149:450-454.
6. Mapel, D. W., J. M. Samet, and D. W. Coultas. 1996. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Chest 110:1058-1067.
7. Turner-Warwick, M., B. Burrows, and A. Johnson. 1980. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 35:171-180.
8. Tukiainen, P., E. Taskinen, P. Holsti, O. Korhola, and M. Valle. 1983. Prognosis of cryptogenic fibrosing alveolitis. Thorax 38:349-355.
9. Raghu, G., W. J. Depaso, K. Cain, S. P. Hammar, C. E. Wetzel, D. F. Dreis, J. Hutchinson, N. E. Pardee, and R. H. Winterbauer. 1991. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 144:291-296.
10. Johnson, M. A., S. Kwan, N. J. C. Snell, A. J. Nunn, J. H. Darbyshire, and M. Turner-Warwick. 1989. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44:280-288.
11. Flaherty, K., J. P. Lynch 3rd, G. Toews, K. Hariharan, R. Strawderman, R. Streiter, E. Kazerooni, A. Flint, and F. Martinez. 1999. High dose versus low dose corticosteroids in the treatment of idiopathic pulmonary fibrosis (IPF) (abstract). Am. J. Respir. Crit. Care Med. 159:A50.
12. Douglas, W. W., J. H. Ryu, S. J. Swensen, K. P. Offord, D. R. Schroeder, G. M. Caron, and R. A. DeRemee. 1998. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 158:220-225.
13. Gay, S. E., E. A. Kazerooni, G. B. Toews, J. P. Lynch 3rd, B. H. Gross, P. N. Cascade, D. L. Spizarny, A. Flint, M. A. Schork, R. I. Whyte, J. Popovich, R. Hyzy, and F. J. Martinez. 1998. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 157:1063-1072.
14. Zisman, D. A., J. P. Lynch 3rd, R. M. Strieter, E. A. Kazerooni, G. B. Toews, and F. J. Martinez. 1998. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed corticosteroids (abstract). Chest 114:2745.
15. Raghu, G., W. C. Johnson, D. Lockhart, and Y. Mageto. 1999. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am. J. Respir. Crit. Care Med. 159:1061-1069.
16. Tan, A., H. Levrey, C. Dahm, V. A. Polunovsky, J. Rubins, and P. Bitterman. 1999. Lovastatin induces fibroblast apoptosis in vitro and in vivo: a possible therapy for fibroproliferative disorders. Am. J. Respir. Crit. Care Med. 159:220-227.
17. Peters, S. G., J. C. McDougall, W. W. Douglas, D. T. Coles, and R. A. DeRemee. 1993. Colchicine in the treatment of pulmonary fibrosis. Chest 103:101-104.
18. Douglas, W. W., J. H. Ryu, J. A. Bjoraker, D. R. Schroeder, J. L. Myers, H. D. Tazelaar, S. J. Swensen, P. D. Scanlon, S. G. Peters, and R. A. DeRemee. 1997. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin. Proc. 72:201-209.
19. 1: prediction equations from a probability sample of Michigan, a large industrial state. Bull. Eur. Physiopathol. Respir. 22:589-597.
20. Miller, A., J. C. Thornton, R. Warshaw, J. Anderson, A. S. Tierstein, and I. J. Selikoff. 1983. Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Am. Rev. Respir. Dis. 127:270-277.
21. Kaplan, E. L., and P. Meier. 1958. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481.
22. Cox, D. R. 1972. Regression models and life-tables (with discussion). J. R. Stat. Soc. Series B 34:187-220.
23. Selman, M., G. Carrillo, J. Salas, R. Perez Padilla, R. Perez-Chavira, R. Sansores, and R. Chapela. 1998. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 114:507-512.
24. Nocturnal Oxygen Therapy Trial Group. 1980. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann. Intern. Med. 93:391-398.
25. 2 therapy. Am. Rev. Respir. Dis. 126:729-733.
26. Hunninghake, G. W., and A. R. Kalica. 1995. Approaches to the treatment of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 151:915-918.
27. Meyer, A., R. Buhl, and H. Magnussen. 1994. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 7:431-436.
28. Behr, J., K. Maier, B. Degenkolb, F. Krombach, and C. Vogelmeier. 1997. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 156:1897-1901.
29. Winget, D. B., E. E. Lower, and R. P. Baughman. 1997. Identification of factors associated with improved survival in IPF treated with cyclophosphamide (abstract). Am. J. Respir. Crit. Care Med. 155:A318.
30. Wells, A. U., M. Rubens, R. duBois, and D. Hansell. 1993. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. A.J.R. 161:1159-1165.
31. Hanson, D., R. Winterbauer, S. Kirtland, and R. Wu. 1995. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 108:305-310.
32. Ryu, J. H., T. V. Colby, and T. E. Hartman. 1998. Idiopathic pulmonary fibrosis: current concepts. Mayo dm. Proc. 73:1085-1101.
33. Johnston, I. D. A., R. J. Prescott, J. C. Chalmers, and R. M. Rudd. 1997. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 52:38-44.
34. Coultas, D. B., R. E. Zumwalt, W. C. Black, and R. E. Sobonya. 1994. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 150:967-972.
35. Hunninghake, G., D. Schwartz, T. King, J. Lynch, J. Hogg, J. Waldron, T. Colby, N. Muller, D. Lynch, J. Galvin, B. Gross, G. Toews, R. Helmers, J. Cooper, R. Baughman, S. Sahn, M. Millard, and J. Stutzman from the IPF Open Lung Biopsy Study Group. 1998. Open lung biopsy in IPF (abstract). Am. J. Respir. Crit. Care Med. 157:A277.
36. Lynch D. A., N. L. Muller, J. Galvin, B. Gross, and G. Hunninghake. 1999. Accuracy of chest CT scanning in the diagnosis of idiopathic pulmonary fibrosis (IPF). Society of Thoracic Radiology Annual Meeting, (abstract, course syllabus: personal communication).